Ogura Toshiro, Muta Yu, Hatano Satoshi, Amano Kunihiko, Ishiguro Toru, Fukuchi Minoru, Inokuma Shigehisa, Kumagai Yoichi, Ishibashi Keiichiro, Mochiki Erito, Ishida Hideyuki
Dept. of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University.
Gan To Kagaku Ryoho. 2018 Feb;45(2):339-341.
The liver is the most common metastatic site for colorectal cancer(CRC).The 5-year survival rate of resected cases has been reported to be about 40%.Hepatic lymph node metastasis is reportedly associated with a poor prognosis in patients with liver metastases of CRC.The incidence of hepatic lymph node involvement in patients with liver metastases of CRC ranges from 5% to 28%.However, few reports have focused on hepatic lymph node involvement in patients with resectable liver metastasis who have undergone preoperative chemotherapy.This retrospective study was undertaken to address this issue.The subjects were 33 consecutive patients who had undergone the resection of liver metastases of CRC with hepatic lymph node sampling after preoperative chemotherapy between 2001 and 2016. Hepatic lymph node metastasis was confirmed in only one patient(3%).There was no significant difference in the frequency of hepatic lymph node metastasis between the cases with or without preoperative chemotherapy.The further collection of data is warranted to elucidate the significance of hepatic lymph node involvement in patients with liver metastases of CRC treated with preoperative chemotherapy.
肝脏是结直肠癌（CRC）最常见的转移部位。据报道，接受手术切除病例的5年生存率约为40%。据报道，肝淋巴结转移与CRC肝转移患者的预后不良有关。CRC肝转移患者肝淋巴结受累的发生率在5%至28%之间。然而，很少有报告关注接受术前化疗的可切除肝转移患者的肝淋巴结受累情况。本回顾性研究旨在解决这一问题。研究对象为2001年至2016年间连续33例在术前化疗后接受CRC肝转移切除并进行肝淋巴结采样的患者。仅1例患者（3%）证实有肝淋巴结转移。术前化疗组和未术前化疗组之间肝淋巴结转移频率无显著差异。有必要进一步收集数据以阐明肝淋巴结受累在接受术前化疗的CRC肝转移患者中的意义。
